Industry / Israel
Teva Wins Approval For Biosimilar Neupogen
September 2008 | Company News AlertIsrael's Teva Pharmaceutical Industries has announced that it has received EU marketing authorisation for TevaGrastim (filgrastim), a biosimilar of Amgen's Neupogen. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analogue used in the treatment of chemotherapy-induced neutropenia. The approval follows a positive appraisal of the product by the European Medicines Agency (EMEA) in February 2008. Teva expects to launch TevaGrastim in the EU during 2009. According to IMS Health, Neupogen had EU sales of US$300mn in the year to June 30 2008, which is almost 25% of its global
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
